US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jun 27, 2012 (14 years ago)

Methotrexate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

What was recalled

Methotrexate Injection, USP, 25 mg/mL, 40 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; NDC 61703-408-41

Recalling firm
Hospira Inc.
NDC code
61703-408-41
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1681-2012

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Methotrexate recalls

See all
Class III · Low risk Completed

Methotrexate Tablets

Reason Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.

Amneal Pharmaceuticals, LLC NDC 69238-1423-1 D-0629-2024
Class III · Low risk Ongoing

Methotrexate Tablets

Reason Failed Tablet/Capsule Specifications: Tablets were observed to have an unsmooth surface with two tablets demonstrating illegible tablet identification and scoring.

West-Ward Columbus Inc D-0066-2024
Class II · Moderate risk Terminated

Methotrexate Intravitreal

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0221-2023
Class II · Moderate risk Terminated

Methotrexate

Reason Lack of Assurance of Sterility

Edge Pharma, LLC NDC 05446-1505-05 D-0406-2022
Class II · Moderate risk Terminated

Methotrexate Injection

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. NDC 61703-350-38 D-0553-2021